title: From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
abstract: Breast cancer is a heterogeneous disease. Thanks to extensive efforts from research scientists and clinicians, treatment for breast cancer has advanced into the era of targeted medicine. With the use of several well-established biomarkers, such as hormone receptors (HRs) (i.e., estrogen receptor [ER] and progesterone receptor [PgR]) and human epidermal growth factor receptor-2 (HER2), breast cancer patients can be categorized into multiple subgroups with specific targeted treatment strategies. Although therapeutic strategies for HR-positive (HR+) HER2-negative (HER2-) breast cancer and HR-negative (HR-) HER2-positive (HER2+) breast cancer are well-defined, HR+ HER2+ breast cancer is still an overlooked subgroup without tailored therapeutic options. In this review, we have summarized the molecular characteristics, etiology, preclinical tools and therapeutic options for HR+ HER2+ breast cancer. We hope to raise the attention of both the research and the medical community on HR+ HER2+ breast cancer, and to advance patient care for this subtype of disease.
authors.affiliation: Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA, United States.
authors.forename: Victoria Shang
authors.initials: VS
authors.lastname: Wu
authors.affiliation: Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA, United States.
authors.forename: Noriko
authors.initials: N
authors.lastname: Kanaya
authors.affiliation: Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Chiao
authors.initials: C
authors.lastname: Lo
authors.affiliation: Department of Medical Oncology and Experimental Therapeutics, City of Hope Medical Center Duarte, CA, United States.
authors.forename: Joanne
authors.initials: J
authors.lastname: Mortimer
authors.affiliation: Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA, United States. Electronic address: schen@coh.org.
authors.forename: Shiuan
authors.initials: S
authors.lastname: Chen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001940:Breast / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000032:analysis / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000032:analysis / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: ERα; HER2; HR+ HER2+ breast cancer; The crosstalk between ER and HER2